Publication Name	World Journal of Clinical Oncology
Manuscript ID	2634
Country	Saudi Arabia

Received	2013-03-05 09:00
Peer-Review Started	2013-03-05 16:02
To Make the First Decision	2013-03-25 15:16
Return for Revision	2013-03-27 16:38
Revised	2013-04-13 04:40
Second Decision	2013-05-07 17:41
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2013-05-08 09:18
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-06-20 14:53
Publish the Manuscript Online	2013-07-06 12:57

ISSN	2218-4333 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Case Report
Article Title	Behavior of advanced gastrointestinal stromal tumor in a patient with von-Recklinghausen disease: Case report
Manuscript Source	Invited Manuscript
All Author List	Samer Sawalhi, Khalid Al-Harbi, Zakaria Raghib, Abdelrahman I Abdelrahman and Ahmed Al-Hujaily
Funding Agency and Grant Number
Corresponding Author	Samer Sawalhi, Assistant Professor, Department of Surgery, Permanent researcher in the Centre of Genetics and Inherited Diseases, College of Medicine-Taibah University, PO Box 30001, Al-Madina, Saudi Arabia. drsawalhi@yahoo.com
Key Words	KIT; Gastrointestinal stromal tumor; Imatinib; Neurofibromatosis type-1; Platelet-derived growth factor receptor-alpha
Core Tip	There are several differences between gastrointestinal stromal tumors (GISTs) in a neurofibromatosis type 1 (NF1) patient and sporadic GISTs with regard to the tumor site, tumor behavior, targeted therapeutic approach, survival, prognosis, and recurrence based on genomic mutations. Wild type GISTs, those that do not have mutations in KIT or platelet-derived growth factor receptor-alpha (PDGFR-?), are typically resistant to imatanib therapy. Mutational analysis is critical in predicting tumor behavior and might individualize targeted therapy. We show that sequencing for KIT and PDGFR-? provide a useful tool in predicting tumor behavior of GIST in a NF1 patient.
Publish Date	2013-07-06 12:57
Citation	Sawalhi S, Al-Harbi K, Raghib Z, Abdelrahman AI, Al-Hujaily A. Behavior of advanced gastrointestinal stromal tumor in a patient with Von-Recklinghausen disease: Case Report. World J Clin Oncol 2013; 4(3): 70-74
URL	http://www.wjgnet.com/2218-4333/full/v4/i3/70.htm
DOI	http://dx.doi.org/10.5306/wjco.v4.i3.70

Full Article (PDF)	WJCO-4-70.pdf
Manuscript File	2634-Review.docx
Answering Reviewers	2634-Answering reviewers.docx
Copyright License Agreement	2634-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	2634-Language certificate.pdf
Peer-review Report	2634-Peer review(s).pdf
Scientific Editor Work List	2634-Scientific editor work list.doc